Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

18P - Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): An update of the phase II, prospective study


31 Mar 2023


Poster Display session


Jiayan Chen


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


J. Chen1, H. zhang2, B.Y. Wang3, J.M. Wen3, X.Y. Xu3, H.T. Li3, M. Fan3

Author affiliations

  • 1 Shanghai/CN
  • 2 Hansoh Pharma, Shanghai/CN
  • 3 Fudan University Shanghai Cancer Center, Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 18P


Aumolertinib is a tolerable third-generation EGFR-TKI that has CNS efficacy in patients with EGFR-mutant NSCLC. Stereotactic radiotherapy (SRT) is highly effective and less toxic for limited intracranial metastases. We aim to investigate the efficacy and safety of aumolertinib followed by SRT in patients with intracranial oligometastatic NSCLC.


Intracranial oligometastatic patients with EGFR sensitive mutations (EGFR-TKIs naive) were enrolled and received aumolertinib 110 mg daily until intracranial disease progression. Then SRT (32–40Gy total, 8Gy/f) was given to intracranial oligo-progression disease. After SRT the patients received continued aumolertinib if extracranial lesions were stable controlled. The primary endpoint was intracranial objective response rate (iORR). Secondary endpoints included intracranial progression-free survival (iPFS), intracranial duration of response (iDOR) according to RECIST 1.1, cerebral radiation necrosis rate (CRNR) and overall survival (OS). Safety was evaluated according to CTCAE v5.0.


To January 6, 2023, a total of 35 patients were enrolled and 32 patients were assessed, and followed for 3 months to 16 months. All patients received 110 mg aumolertinib daily and received at least one independent imaging evaluation by a radiologist. After administration of aumolertinib, the best response of all patients in intracranial and extracranial lesions was partial response (PR), with an iORR of 100%. At data cut-off, one patient developed intracranial primary lesion progression at 12 months after aumolertinib treatment but stable in extracranial lesions. SRT treatment was given to this patient. No grade ≥3 adverse events occurred after continued aumolertinib. The most common adverse reactions were rash and abnormal liver enzymes.


This report showed pronounced intracranial objective response benefit with aumolertinib in patients with intracranial oligometastatic disease followed by SRT after intracranial oligo-progression and no new safety signals. Aumolertinib has promising efficacy and good tolerability in intracranial oligometastatic EGFR mutated NSCLC.

Clinical trial identification


Legal entity responsible for the study

The authors.


Hansoh Pharmaceutical Group Company Limited.


H. Zhang: Financial Interests, Personal, Sponsor/Funding: Hansoh Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.